Independent observational research · GLP-3 is investigational and not FDA-approved

What are we trying to learn?

The questions behind the stories

We publish the questions before we publish the answers. Every R3TA report maps back to one of the questions below, so readers can see what we set out to observe — and what we did not.

  1. 01

    Weight

    How does self-reported weight change over 4, 12, 24 and 26 weeks?

  2. 02

    Appetite

    When do participants first report meaningful changes in hunger, satiety and food noise?

  3. 03

    Side effects

    Which side effects are most commonly reported, when do they emerge, and how long do they persist?

  4. 04

    Body composition

    Where available, how do fat mass and lean mass change over time?

  5. 05

    Lifestyle

    How do participants report changes in energy, exercise, sleep and everyday activity?

  6. 06

    Previous GLP-1 experience

    Do people reporting previous semaglutide or tirzepatide use describe different experiences?

  7. 07

    Discontinuation

    Why do participants report stopping?

  8. 08

    Variability

    Why do some people report dramatically different experiences from others?